Excerpt:Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Excerpt:...- Advanced or metastatic breast cancer that is HER-2 negative (HR positive or HR negative)...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Olaparib In Metastatic Breast Cancer
Excerpt:...- Patients with hormone receptor-positive (estrogen and/or progesterone receptor-positive) disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy....
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Excerpt:...Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
Excerpt:...Subjects with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
Excerpt:...Participants with hormone receptor-positive (estrogen and/or progesterone receptor-positive) disease must have received and progressed on at least one endocrine therapy (adjuvant or metastatic), or have disease that the treating physician believes to be inappropriate for endocrine therapy....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Excerpt:...- Patients with hormone receptor positive disease who discontinue endocrine therapy two weeks prior to initiating study treatment are eligible...